VistaraBio seeks collaborators for co-development and commercialization of its platforms, products and services.

VistaraBio is advantageously positioned for emerging applications of cereblon biology with its proprietary knowledge and customized assay tools, and hopes to be a prominent contributor for accelerated growth. These areas present multiple opportunities for collaborative development with third parties. The cereblon discovery space is evolving rapidly, highlighting the multi-faceted role of this fascinating protein! The current environment promises rapid innovation for new drug discovery into applications other than the burgeoning field of Targeted Protein degradation [TPD], which is already a hotly competitive area. VistaraBio is ready to scale!

While iMiDs target many Znfs, the total number of proteins in this group which can be efficiently degraded is relatively small compared with the large size of this gene family in humans. Identifying molecular glue analogs with selectivity towards the Znf of interest has been challenging. To overcome this problem, VistaraBio has identified Znfs which are agnostic to iMiDs, suggesting an opportunity to co-opt a different E3 ligase (than cereblon) to target them. This represents another important area for collaboration to achieve accelerated validation and progress of promising candidates into the clinic in oncology.